Silence Therapeutics (SLN) Fundamental Analysis: Revenue, Earnings & Valuation

5.20 / 10

Netural

Fundamental analysis rates the stock as Neutral with a 5.2/10 score. Revenue‑MV and Profit‑MV are positive, and inventory turnover is strong, but current and fixed asset turnover are weak, and gross margin is low. Overall, fundamentals are fair, urging caution.

Analysis Checks(6/10)

Revenue-MV

Value-7.29

Score2/3

Weight22.33%

1M Return8.05%

Inventory turnover ratio

Value106.57

Score3/3

Weight19.32%

1M Return6.65%

Gross profit margin (%)

Value61.54

Score0/3

Weight-9.26%

1M Return-5.42%

Profit-MV

Value0.68

Score2/3

Weight18.17%

1M Return6.36%

Income tax / Total profit (%)

Value-0.01

Score1/3

Weight0.45%

1M Return0.21%

Current assets turnover ratio

Value0.00

Score0/3

Weight-3.39%

1M Return-1.61%

Fixed assets turnover ratio

Value0.30

Score1/3

Weight-2.36%

1M Return-1.13%

Cost of sales ratio (%)

Value38.46

Score2/3

Weight-7.45%

1M Return-3.62%

Asset-MV

Value-0.55

Score2/3

Weight44.39%

1M Return13.10%

Cash-MV

Value0.03

Score2/3

Weight17.80%

1M Return6.19%

Is SLN fundamentally strong?

SLN scores 5.20/10 on fundamentals and holds a Fair valuation at present. Backed by its -90.27% ROE, -15851.88% net margin, -2.92 P/E ratio, 4.15 P/B ratio, and -90.91% earnings growth, these metrics solidify its Netural investment rating.